Key highlights
- LENZELTA vaccine (Boehringer Ingelheim) targets Staphylococcus aureus and Escherichia coli, key bovine mastitis pathogens.
- Given as two doses during the dry‑off period for cows and heifers.
- Offers early onset of immunity and up to six months' protection with an oil‑free adjuvant; available in several EU countries from April 2026.
Overview
LENZELTA is a bovine vaccine shown to significantly reduce the incidence and severity of clinical mastitis in vaccinated cows and heifers and will be available in several EU countries from April 2026.
Target pathogens and protection
The vaccine targets Staphylococcus aureus and Escherichia coli, offering an early onset of immunity and protection lasting up to six months against these two key mastitis pathogens.
Administration and formulation
LENZELTA is administered as two doses during the dry‑off period, uses an oil‑free adjuvant, and is supplied in multiple vial sizes to fit herd‑health routines.
Disease context
Mastitis remains widespread and economically significant in dairy herds, reducing milk quality and yield; cows are particularly vulnerable around calving, so preventive measures during dry‑off are important.
